Cargando…

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial

The attainment of target hemoglobin levels in hemodialysis patients is low. Several factors play a role, such as hyporesponsiveness to erythropoiesis‐stimulating agents (ESA), but also suboptimal prescribing of ESA and iron. The goal of this study was to investigate if a pharmacist‐managed dosing al...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Oever, Francisca Johanna, Heetman‐Meijer, Carolien F. M., Birnie, Erwin, Vasbinder, Erwin C., Swart, Eleonora L., Schrama, Yvonne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383089/ https://www.ncbi.nlm.nih.gov/pubmed/32715653 http://dx.doi.org/10.1002/prp2.628

Ejemplares similares

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial
por: Forni, Valentina, et al.
Publicado: (2013)

Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009)

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
por: Schaefer, Franz, et al.
Publicado: (2015)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
por: Mafodda, Antonino, et al.
Publicado: (2017)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
por: Chen, Nan, et al.
Publicado: (2022)

JR‐131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double‐Blinded, Parallel‐Group Phase 3 Study
por: Nishi, Shinichi, et al.
Publicado: (2019)

Long‐Term Safety and Efficacy of JR‐131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study
por: Nishi, Shinichi, et al.
Publicado: (2019)

Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
por: Egrie, J, et al.
Publicado: (2002)

Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells
por: Andreucci, Michele, et al.
Publicado: (2021)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature
por: Libudzic-Nowak, Anna Maria, et al.
Publicado: (2018)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
por: Deger, Melike, et al.
Publicado: (2012)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
por: Platzbecker, U, et al.
Publicado: (2017)

Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
por: Tani, Junya, et al.
Publicado: (2020)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients
por: Barbieri, Carlo, et al.
Publicado: (2016)

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
por: Berbec, Nicoleta Mariana, et al.
Publicado: (2018)

Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
por: Boccia, Ralph V., et al.
Publicado: (2016)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ek5qed5bdmnj1mi75q4skvkmj4